Read More Pharma Industry News Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer Chronos-3 trial results : Bayer said that the investigational combination of Aliqopa (copanlisib) and rituximab considerably increased progression-free… bySrinathApril 11, 2021
